RP is a rare, inherited degenerative disease that damages light-sensitive cells in the retina, resulting in decreased vision at night or in low light; loss of side (peripheral) vision; and loss of central vision as the disease …

The Argus II implant, manufactured by the US firm Second Sight, has previously been used to restore some vision to patients who are blind as a result …

Some …

Mark Humayun, the biological engineer who co-invented the Argus II, says that the team expects FDA approval within the next few months, and thinks …

Mark Humayun. As technology improves, so will your Argus II implant – without the need for additional surgery. #20 Argus II Retinal Implant: Manufactured by Second Sight Medical Products and co-invented by Mark Humayun of the USC Eye Institute, the Argus II Retinal Prosthesis System was first approved by the U.S. Food and Drug Administration in 2013 to treat adult patients with advanced retinitis pigmentosa (RP); it had been approved in Europe two years earlier.

Enjoy programming flexibility, and the capacity for future hardware and software upgrades. This manuscript discusses: 1- Argus-II retinal prostheses description, 2- case selection and screening, 3- surgical procedure, 4- safety, performance outcome and utility, 5-device programming and 6- neurovisual and cognitive rehabilitation, to highlight recommendations toward optimizing patient outcomes with the Argus-II system. Second Sight first won approval in Europe in 2011 for the Argus II, followed by an FDA approval in 2013 (see “Bionic Eye Implant Approved for U.S. Patients”). 8 Mean age was 58 years (range of 28-77 years). The As III produced 190 hp (140 kW). Twitter Share . The device, called the Argus II Retinal Prosthesis System, was developed by a California-based company called Second Sight.

The Argus II has been used to restore some level of visual perception to hundreds of individuals with severe retinitis pigmentosa — a disease that affects one in 5,000 people. Second Sight’s legacy product, Argus® II, approved by the FDA for the treatment of retinitis pigmentosa, has been implanted in 350+ individuals worldwide, restoring functional, artificial vision by renewing light perception and transforming the daily experience in the majority of individuals. Facebook Count. New clinical trial results from the Argus II Study Group, an international consortium of eye and vision researchers, confirm that the Argus II, also called the “bionic eye,” is a safe, reliable, and effective device that “significantly improves visual function and quality of life for people blinded by retinitis pigmentosa.”. The objective of this study was to assess the cost-effectiveness of the Argus® II Retinal Prosthesis System (Argus II) in retinitis pigmentosa (RP) patients. Dagnelie is part of the original team that invented the device.

Argus II not only made the best of what’s new list, but took top honor in Health, and was deemed the invention of the year for 2013. Method: [A model] was developed to determine the cost-effectiveness of Argus II versus usual care in RP from the perspective of healthcare payer.